Biotech Values

[ocyanblue]

I am curious as to why you seem to think that it is a negative if certain analyses for survival were done in D9901 during looks at the TTP and pain endpoints. The protocol said to follow for 3 years for survival and there was no provision to stop early on that. So it shouldn't matter how many of those they did as they never got multiple hits for survival.

They might have tried for AA if TTP was met and that might have been thought of as another hit on the data and a cause to reduce the alpha for the survival endpoint. But even that consideration is questionable as current thinking is that alpha need not be penalized for dependent endpoints.